glp 1 combination Arguments in favor of early therapy. GLP1-Ag glucagon-like The combination of glucagon-like peptide-1

Gastroenterology 2007

Frequently Asked Questions Orforglipron (LY3502970) is an investigational oral, non-peptide, small-molecule GLP-1 receptor agonist developed by Eli Lilly

It could increase hepatic glucose output and worsen glycemia

This study showed that the risk of recurrent pancreatitis in a cohort of patients taking GLP-1 receptor agonists (10%) was likely no greater than what is observed in the general population and that more than half of the episodes of recurrent pancreatitis were attributable to causes other than GLP-1 receptor agonist therapy

However, significant weight loss from Wegovy may eventually require adjustments to your thyroid medication, as thyroid hormone doses are typically based on your weight